Dr. Mridula A. George
Medical Oncology (Medical Oncology Physician)
195 Little Albany St
New Brunswick, NJ 08901
Who else practices at this address →
Middlesex County includes mental health (21% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Rutgers New Jersey Medical School (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 129
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Rutgers New Jersey Medical School
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NJ license 25MA09724500 -
Hematology & Oncology Physician
NJ license 25MA09724500 -
Internal Medicine Physician
MA license 252822
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Robert Wood Johnson University Hospital New Brunswick, NJ
Medical groups
- Rutgers Health-Rwj Scleroderma Program (391 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 129
- Services billed
- 408
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 106 | 69 |
| Established patient office or other outpatient visit, 40-54 minutes | 99 | 36 |
| New patient office or other outpatient visit, 60-74 minutes | 27 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in New Brunswick, NJ | 179 |
| Tamoxifen Citrate Other prescribers in New Brunswick, NJ | 88 |
| Anastrozole Other prescribers in New Brunswick, NJ | 52 |
| Ibrance (palbociclib) | 47 |
| Gabapentin Other prescribers in New Brunswick, NJ | 23 |
| Ondansetron Hcl Other prescribers in New Brunswick, NJ | 20 |
| Exemestane | 16 |
| Pantoprazole Sodium Other prescribers in New Brunswick, NJ | 11 |
| Prochlorperazine Maleate Other prescribers in New Brunswick, NJ | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 15 payments worth $6,469 in total to this clinician.
| Genentech USA, Inc. | $3,398 |
|---|---|
| Novartis Pharmaceuticals Corporation | $2,792 |
| Daiichi Sankyo Inc. | $128 |
| Gilead Sciences, Inc. | $99.00 |
| Stemline Therapeutics Inc. | $28.51 |
| Janssen Biotech, Inc. | $24.11 |
| Consulting Fee | $5,356 |
|---|---|
| Food and Beverage | $570 |
| Travel and Lodging | $355 |
| Education | $189 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Jul 10, 2025 | Consulting Fee Herceptin; Perjeta; Phesgo · BioOncology | $2,731 |
| Novartis Pharmaceuticals Corporation Sep 22, 2025 | Consulting Fee KISQALI · Oncology | $2,625 |
| Genentech USA, Inc. Jul 10, 2025 | Travel and Lodging Herceptin; Perjeta; Phesgo · BioOncology · travel to New York City, NY | $355 |
| Gilead Sciences, Inc. Dec 3, 2025 | Education Trodelvy · ONC · in-kind Company’s description;4252209;GTF;19172797 | $99.00 |
| Daiichi Sankyo Inc. Jul 24, 2025 | Education Enhertu · ONCOLOGY · in-kind | $22.50 |
| Daiichi Sankyo Inc. May 2, 2025 | Education Enhertu · ONCOLOGY · in-kind | $22.50 |
| Daiichi Sankyo Inc. May 5, 2025 | Education Enhertu · ONCOLOGY · in-kind | $22.50 |
| Daiichi Sankyo Inc. Jun 26, 2025 | Education Enhertu · ONCOLOGY · in-kind | $22.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 7 companies. The companies reported $991,161 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
AstraZeneca Pharmaceuticals LP - A randomized doubleblind phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2 breast cancer HER2CLIMB05
Pfizer Inc. - Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
Genentech, Inc. - An interventional openlabel randomized multicenter phase 3 study of PF07220060 plus letrozole compared to CDK46 inhibitor plus letrozole in participants over 18 years of age with hormone receptor hrpositive HER2NEGATI…
Pfizer Inc. - BNT327
BioNTech SE - CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase In…
AstraZeneca UK Limited - BNT327-02
BioNTech SE - Randomized doubleblind phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine TDM1 for subjects with unresectable locallyadvanced or metastatic HER2 breast cancer HER2CLIMB02
Pfizer Inc. - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT Sacituzumab Tirumotecan, MK-2870 Followed by Carboplatin,Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neo…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.